Register as a signatory Sign in

Governance

LifeTrain is coordinated by the EMTRAIN project on behalf of the Innovative Medicines Initiative’s Education and Training projects.

 

Many representatives from across all four projects have provided invaluable input to our core project team, which comprises:

  • Mike Hardman, AstraZeneca, Alderley Park, Macclesfield, UK, representing EMTRAIN, PharmaTrain and EUPATI
  • Cath Brooksbank, European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK, representing EMTRAIN and ELIXIR
  • Christa Janko, Medizinische Universität Wien, Vienna, Austria, representing EMTRAIN
  • Claire Johnson, European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK, representing EMTRAIN and ELIXIR
  • Wolf See, for Bayer Pharma AG, Berlin, Germany, representing EMTRAIN, PharmaTrain and EUPATI
  • Hans Lindén, European Federation for Pharmaceutical Sciences, Järfälla, Sweden, repreenting SafeSciMET and PharmaTrain (and 
    EUFEPS)
  • Patrice Verpillat, H. Lundbeck A/S, Issy-les-Moulineaux, France, representing Eu2P
  • Pierre Lafolie, Karolinska Institutet, Stockholm, Sweden, representing EMTRAIN and ECRIN
  • Berith Bjørnholm, H. Lundbeck A/S, Valby, Denmark, representing EMTRAIN
  • Monique Jansen, Genzyme Europe BV, Naarden, The Netherlands, representing EMTRAIN
  • Tiina Koivisto, Orion Pharma, Espoo, Finland, representing EMTRAIN
  • Lorraine Gough, University of Oxford, UK, representing EMTRAIN and INSTRUCT
  • Jose Luis Diaz, Almirall R&D Centre, Barcelona, Spain, representing EMTRAIN
  • Santiago Puig, Esteve, Barcelona, Spain, representing EMTRAIN
  • Heinrich Klech, EFGCP, Vienna, Austria, representing PharmaTrain

The Innovative Medicines Initiative (IMI) is Europe’s largest public–private partnership; it is a joint undertaking between the European Commission and the European Federation of Pharmaceutical Industries and Associations. Through a series of innovative Education and Training Programmes, IMI aims to address the current lack of holistic, integrative and translational approaches in education and training, and is therefore a unique part of a broader effort to strengthen Europe’s competitiveness in medicines R&D in the face of increased global competition.

Feedback on-course.eu